Design of a prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey

摘要

Background: In Japan, intravenous digoxin was previously recommended as a standard drug for acute control of the heart rate in atrial fibrillation (AF)/atrial flutter (AFL) patients with chronic heart failure (CHF). Treatment alternatives for such cases were limited and new drugs for this purpose are needed. In November 2013, landiolol hydrochloride (Onoact (R) 50 for Injection, Ono Pharamaceutical, Osaka, Japan) was approved with the indication for "tachyarrhythmia (AF/AFL) in patients with cardiac dysfunction." However, clinical experience with this condition is still insufficient. Therefore, it is important to conduct a surveillance of landiolol under actual clinical settings. In addition, collecting data on the mid- and long-term outcomes in patients treated with landiolol which have not been collected in clinical trials are indispensable.